Skip to main content
MorphoSys gains option for Vivoryon's QPCTL inhibitors program
7/11/2019

MorphoSys has obtained an exclusive option for international rights to develop and market Vivoryon Therapeutics's family of QPCTL inhibitors. The small molecule glutaminyl-peptide cyclotransferase-like inhibitors will be used to develop cancer therapies in combination with MorphoSys' own candidate tafasitamab, or MOR208, to treat relapsed/refractory diffuse large B-cell lymphomas.

Full Story: